Article
Oncology
Leslie Ballas, Parminder Singh, Seth P. Lerner
Summary: Radical cystectomy with bilateral pelvic lymphadenectomy and trimodality bladder-sparing therapy are both effective treatment options for patients with nonmetastatic muscle invasive bladder cancer. Multidisciplinary evaluation and unbiased discussion should be provided to eligible patients. The barriers to broader acceptance and utilization of trimodality bladder-sparing therapy are discussed, and support for clinical trials is encouraged.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Oncology
Rahul Krishnatry, Priyamvada Maitre, Anuj Kumar, Tejshri Telkhade, Ganesh Bakshi, Gagan Prakash, Mahendra Pal, Amit Joshi, Santosh Menon, Vedang Murthy
Summary: This study aimed to evaluate urinary symptoms and urine cytology as screening tools for cystoscopic detection of local recurrence after bladder-preserving trimodality treatment (TMT). The results showed that urinary symptoms and urine cytology were effective in predicting local recurrence in cystoscopic biopsy. The combination of cystoscopy and urine cytology was particularly sensitive in detecting muscle-invasive recurrence, while alternate cystoscopy may be more optimal for detecting any local recurrence.
Article
Oncology
Trevor J. Royce, Yuan Liu, Matthew Milowsky, Jason A. Efstathiou, Ashesh B. Jani, Benjamin Fischer-Valuck, Sagar A. Patel
Summary: Adding neoadjuvant chemotherapy to definitive chemoradiation for muscle-invasive bladder cancer did not show a survival benefit in this retrospective study, suggesting that routine addition of neoadjuvant chemotherapy to this treatment should be further investigated through prospective clinical trials.
CLINICAL GENITOURINARY CANCER
(2021)
Article
Medicine, General & Internal
Anthony M. Magliocco, Jennifer Moughan, David T. Miyamoto, Jeff Simko, William U. Shipley, Phillip J. Gray, Michael P. Hagan, Matthew Parliament, William J. Tester, Anthony L. Zietman, Susan McCarthy, Daryoush Saeed-Vafa, Yin Xiong, Taylor Ayral, Alan C. Hartford, Ashish Patel, Seth A. Rosenthal, Susan Chafe, Richard Greenberg, Michael A. Schwartz, Mark E. Augspurger, John A. Keech, Kathryn A. Winter, Felix Y. Feng, Jason A. Efstathiou
Summary: This study evaluated MRE11 expression as a prognostic biomarker in MIBC patients receiving trimodality therapy, using automated quantitative image analysis. The results demonstrated that higher MRE11 signal ratios were associated with better disease-specific mortality, while lower MRE11 signal ratios identified a poor prognosis subgroup that may benefit from intensification of therapy.
Article
Oncology
Yaxiong Tang, Lede Lin, Yunfei Xiao, Linghao Meng, Yujia Yang, Xiang Li
Summary: Compared to radical cystectomy, trimodality therapy is becoming increasingly utilized for patients with muscle-invasive bladder cancer. However, achieving satisfactory oncological outcomes requires strict patient selection criteria, and the comparative outcomes of trimodality therapy versus radical cystectomy remain controversial.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Article
Medicine, Research & Experimental
Yi-Xin Zhou, Qian-Cheng Hu, Ya-Juan Zhu, Xiao-Li Mu, Ji-Yan Liu, Ye Chen
Summary: This study compared the prognosis of MIBC patients receiving TMT and NAC + RC. The results showed that patients receiving NAC + RC had significantly better prognosis than those receiving TMT.
EUROPEAN JOURNAL OF MEDICAL RESEARCH
(2023)
Article
Oncology
Alexandre R. Zlotta, Leslie K. Ballas, Andrzej Niemierko, Katherine Lajkosz, Cynthia Kuk, Gus Miranda, Michael Drumm, Andrea Mari, Ethan Thio, Neil E. Fleshner, Girish S. Kulkarni, Michael A. SJewett, Robert G. Bristow, Charles Catton, Alejandro Berlin, Srikala S. Sridhar, Anne Schuckman, Adam S. Feldman, Matthew Wszolek, Douglas M. Dahl, Richard J. Lee, Philip J. Saylor, M. Dror Michaelson, David Miyamoto, Anthony Zietman, William Shipley, Peter Chung, Siamak Daneshmand, Jason A. Efstathiou
Summary: A retrospective analysis of 722 patients with muscle-invasive bladder cancer found no significant differences in survival outcomes between trimodality therapy and radical cystectomy, suggesting that trimodality therapy should be offered to all suitable candidates.
Review
Andrology
Xinxiang Fan, Wang He, Jian Huang
Summary: In recent years, less-invasive bladder-sparing trimodal therapy (TMT) has been increasingly used for selected patients with muscle-invasive bladder cancer (MIBC) who are unfit for or decline radical cystectomy (RC). This review summarizes the current evidence and future perspectives of bladder-sparing therapy for MIBC. TMT is a well-tolerated and curative alternative to RC for selected patients with localized MIBC, and the emergence of immunotherapy may further improve its effectiveness.
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2023)
Review
Andrology
Xinxiang Fan, Wang He, Jian Huang
Summary: In recent years, the use of less-invasive bladder-sparing trimodal therapy (TMT) for selected patients with muscle-invasive bladder cancer (MIBC) who are unfit for radical cystectomy (RC) has been increasing. This review summarizes the current evidence and future perspectives of bladder-sparing therapy for MIBC. Combination therapy is more effective than monotherapy, and radiotherapy alone has poorer outcomes compared to chemoradiotherapy. Appropriate patient selection and a multi-disciplinary approach are crucial for successful bladder-sparing therapy.
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2023)
Article
Multidisciplinary Sciences
Won Sik Ham, Jee Soo Park, Won Sik Jang, Young Deuk Choi, Jongchan Kim
Summary: The study suggests a correlation between larger prostate volume and worse recurrence and progression-free survival in non-muscle invasive bladder cancer.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
Hannah Slovacek, Jerry Zhuo, Jennifer M. Taylor
Summary: NMIBC is a heterogeneous malignancy with high recurrence and progression rates, necessitating uniform recommendations for diagnosis and management. Guidelines worldwide have adopted risk-stratification at diagnosis to provide evidence-based treatment and surveillance recommendations. Improved endoscopic technologies enhance NMIBC detection and decrease recurrence.
CURRENT ONCOLOGY REPORTS
(2021)
Article
Oncology
Nikhil V. Kotha, Abhishek Kumar, Tyler J. Nelson, Edmund M. Qiao, Alex S. Qian, Rohith S. Voora, Rana R. Mckay, Brent S. Rose, Tyler F. Stewart
Summary: This study suggests that a short-term delay in definitive therapy may not affect long-term outcomes for patients with MIBC undergoing CRT. It provides information to aid patients and clinicians navigate the unique challenges of MIBC care in both pandemic and non-pandemic times.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Review
Biochemistry & Molecular Biology
Francesco Claps, Nicola Pavan, Luca Ongaro, Domenico Tierno, Gabriele Grassi, Carlo Trombetta, Gabriele Tulone, Alchiede Simonato, Riccardo Bartoletti, Laura S. Mertens, Bas W. G. van Rhijn, Maria Carmen Mir, Bruna Scaggiante
Summary: Urothelial carcinoma is a common type of cancer, with bladder carcinoma being the most prevalent form. For non-muscle-invasive bladder cancer that does not respond to BCG treatment, radical cystectomy is currently the standard treatment. However, this surgery carries high risks and impacts the patient's quality of life, highlighting the need for alternative bladder-preserving therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Giulio Francolini, Simona Borghesi, Sergio Fersino, Alessandro Magli, Barbara Alicja Jereczek-Fossa, Luca Cristinelli, Mimma Rizzo, Renzo Corvo, Giovanni L. Pappagallo, Stefano Arcangeli, Stefano Maria Magrini, Rolando M. D'Angelillo
Summary: Comparing trimodality therapy (TMT) and radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC), it was found that TMT could be considered as an alternative treatment to RC in non-metastatic MIBC patients deemed fit for surgery. The study concluded that there was substantial equivalence in overall survival and cancer-specific survival at 5 years between TMT and RC.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Health Care Sciences & Services
Zin W. Myint, Zena Chahine, Rani Jayswal, Emily Bachert, Robert J. McDonald, Stephen E. Strup, Andrew C. James, Patrick J. Hensley, Derek B. Allison
Summary: CD47 is often overexpressed in tumor cells and has been associated with adverse clinical outcomes in various malignancies. In this study, CD47 expression was detected in 44% of tumor samples from muscle invasion bladder cancer patients, but it was not predictive or prognostic. However, there was a trend of decreased CD47 levels from initial tumor samples to matched radical cystectomy specimens in patients receiving neoadjuvant chemotherapy.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Oncology
Coralea Kappel, Di Maria Jiang, Bryan Wong, Tong Zhang, Shamini Selvarajah, Evan Warner, Aaron R. Hansen, Nazanin Fallah-Rad, Adrian G. Sacher, Tracy L. Stockley, Philippe L. Bedard, Srikala S. Sridhar
Summary: Comprehensive genomic profiling using archival tissue was feasible in a cohort of patients with highly treatment resistant metastatic castrate sensitive prostate cancer, and about one third of patients carried de novo AR, DDR pathogenic and/or likely pathogenic variants prior to initiating androgen deprivation therapy (ADT). These findings are important in characterizing patients who were not well represented in landmark clinical trials.
CLINICAL GENITOURINARY CANCER
(2022)
Article
Urology & Nephrology
Robert J. Hamilton, Christina Canil, Noa Shani Shrem, Kopika Kuhathaas, Maria (Di) Jiang, Peter Chung, Scott North, Piotr Czaykowski, Sebastien Hotte, Eric Winquist, Christian Kollmannsberger, Armen Aprikian, Denis Soulieres, Scott Tyldesley, Alan So, Nicholas Power, Ricardo A. Rendon, Martin O'Malley, Lori Wood
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL
(2022)
Editorial Material
Urology & Nephrology
Kristen McAlpine, Roderick Clark, Maria Jiang, Aaron Hansen, Otto Hemminki, Robert J. Hamilton
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL
(2022)
Article
Medicine, General & Internal
Raj Vikesh Tiwari, Maria Di Jiang, Keith Jarvi, Robert Hamilton
Summary: In this case report, a patient with enlarged retroperitoneal nodes and elevated HCG levels during treatment for subfertility with clomiphene citrate is presented. The patient's condition improved after further examinations and follow-up.
Review
Oncology
Jenny Peng, Srikala Sridhar, Arlene Odelia Siefker-Radtke, Shamini Selvarajah, Di Maria Jiang
Summary: As our understanding of cancer genomics improves, precision medicine is becoming more popular. FGFR has been identified as one of the oncogenic driver pathways in urothelial carcinoma, and targeted drug development has shown promise. Erdafitinib is the only FGFR inhibitor currently approved by FDA for platinum-refractory metastatic urothelial carcinoma with FGFR2/3 alterations, and it has shown higher response rates compared to second-line chemotherapy or immunotherapy. This review summarizes the clinical data supporting FGFR inhibition and discusses ways to optimize its use in routine clinical practice.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Article
Urology & Nephrology
Adam Bobrowski, Lynn Anson-Cartwright, Kopika Kuhathaas, Di Maria Jiang, Peter Chung, Philippe Bedard, Padraig Warde, Martin O'Malley, Joan Sweet, Robert J. Hamilton
Summary: Lactate dehydrogenase does not independently contribute to early relapse detection in stage I seminoma or nonseminomatous germ cell tumor. Elevated lactate dehydrogenase values were documented in a high proportion of nonrelapsing seminoma and nonseminomatous germ cell tumor cases.
JOURNAL OF UROLOGY
(2022)
Review
Oncology
Carlos E. Stecca, Marie Alt, Di Maria Jiang, Glaucia Michelis, Nazanin Fallah-Rad, Sharlene Gill, Mary Elliot, Srikala S. Sridhar
Summary: The study aimed to understand the impact of the COVID-19 pandemic on the wellbeing of international fellows in the Hematology and/or Oncology fellowship program. The findings revealed a decline in overall wellbeing among international fellows, with issues such as separation from family, stress, and fatigue.
SEMINARS IN ONCOLOGY
(2022)
Article
Oncology
Carlos E. Stecca, Di Maria Jiang, Zachary Veitch, Sebastian J. Hotte, Nimira Alimohamed, Lori Wood, Srikala S. Sridhar
Summary: We conducted an online survey of genitourinary medical oncologists in Canada and found that the COVID-19 pandemic has led to an increased use of ARATs and a reduced use of docetaxel in the treatment of mHSPC, and this trend is expected to continue post-pandemic.
CLINICAL GENITOURINARY CANCER
(2023)
Editorial Material
Urology & Nephrology
Ricardo A. Rendon, Sebastien J. Hotte, Scott C. Morgan, Peter C. Black, Maria Jiang, Melissa J. Huynh, Lori A. Wood
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL
(2022)
Article
Oncology
Jakob Lauritsen, Nicolas Sauve, Alexey Tryakin, Di Maria Jiang, Robert Huddart, Daniel Y. C. Heng, Angelika Terbuch, Eric Winquist, Michal Chovanec, Marcus Hentrich, Christian D. Fankhauser, Jonathan Shamash, Xavier Garcia del Muro, David Vaughn, Axel Heidenreich, Cora N. Sternberg, Christopher Sweeney, Andrea Necchi, Carsten Bokemeyer, Mikkel Bandak, Abolghassem Jandari, Laurence Collette, Silke Gillessen, Joerg Beyer, Gedske Daugaard
Summary: Patients with relapsed clinical stage I germ-cell tumors have similar prognosis compared to those with de novo metastatic disease, and unnecessary toxicity may be avoided in intermediate and poor prognosis relapses with intensified treatments.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Esmail M. Al-Ezzi, Amer Zahralliyali, Aaron R. Hansen, Robert J. Hamilton, Michael Crump, John Kuruvilla, Lori Wood, Lucia Nappi, Christian K. Kollmannsberger, Scott A. North, Eric Winquist, Denis Soulieres, Sebastien J. Hotte, Di Maria Jiang
Summary: This study aimed to investigate the treatment practices, selection, and management strategies of metastatic germ cell tumor (GCT) in Canada. The results showed that high-dose chemotherapy (HDCT) is commonly used as salvage therapy for GCT in Canada. However, there are significant differences in treatment availability, selection, and delivery of HDCT among different medical centers.
Review
Oncology
Abhenil Mittal, Srikala S. Sridhar, Michael Ong, Di Maria Jiang
Summary: The treatment paradigm for metastatic castrate-sensitive prostate cancer (mCSPC) has rapidly evolved with the approval of life-prolonging therapies. However, there are still unanswered questions regarding the benefit of docetaxel in combination with androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI), optimal patient selection, and clinical and genomic biomarkers. Real-world data also suggest suboptimal treatment intensification. This article reviews phase-three data on triplet therapy in mCSPC and highlights knowledge gaps and ongoing studies that may change the treatment paradigm.
Article
Oncology
Xin Wang, Osvaldo Espin-Garcia, Di Maria Jiang, Michael J. Allen, Lucy X. Ma, Yvonne Bach, Eric X. Chen, Gail Darling, Johnathan C. Yeung, Rebecca K. S. Wong, Patrick Veit-Haibach, Sangeetha Kalimuthu, Raymond W. Jang, Elena Elimova
Summary: Metastatic gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with a poor prognosis. The site of metastatic disease affects survival, with patients having lymph node only disease having the longest survival and those with lung or bone metastases having shorter survival. Prognostic models should consider the impact of sites of metastasis.
Article
Urology & Nephrology
Peter J. Gariscsak, Lynn Anson-Cartwright, Eshetu G. Atenafu, Di Maria Jiang, Peter Chung, Philippe Bedard, Padraig Warde, Martin O'Malley, Joan Sweet, Rachel M. Glicksman, Robert J. Hamilton
Summary: By decreasing surveillance intensity, the relapse rate and time to relapse in patients with clinical stage I testicular germ cell tumors can be reduced.
EUROPEAN UROLOGY OPEN SCIENCE
(2022)
Article
Oncology
Husam A. Alqaisi, Carlos Stecca, Zachary W. Veitch, Jamila Riromar, Jeenan Kaiser, Nazanin Fallah-Rad, Di Maria Jiang, Scott North, Sunil Samnani, Nimira Alimohamed, Srikala S. Sridhar
Summary: This retrospective study suggests that the presence of bone metastasis (BM) in patients with metastatic urothelial cancer (mUC) is associated with worse overall survival (OS), indicating that BM may be an independent negative prognostic factor. Including BM as a stratification factor in future mUC clinical trial designs may be warranted.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
